Artiva Biotherapeutics, Inc. (ARTV) vs Sol-Gel Technologies Ltd. (SLGL)

Artiva Biotherapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Artiva Biotherapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($202.9M and $199.8M). Artiva Biotherapeutics, Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (0.00% vs −6,630.2%). Across the 12 metrics below, Artiva Biotherapeutics, Inc. leads on 9 and Sol-Gel Technologies Ltd. on 3.

Valuation

Metric ARTV SLGL Biotechnology median
P/E n/m n/m 10.60
P/S n/m 111.18 9.40
P/B 0.47 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 1.99 n/m 0.66
EV/Sales n/m 120.87 9.02
Earnings yield (79.52%) (9.24%) (32.88%)
Free cash flow yield (47.02%) (10.66%) (23.13%)

Profitability

Metric ARTV SLGL Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (36.58%) (40.85%) (51.96%)
Return on assets (33.76%) (35.11%) (46.06%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric ARTV SLGL Biotechnology median
Revenue growth (TTM) — (92.50%) 6.76%
EPS growth (last fiscal year) 40.96% 42.37% 29.88%
Revenue growth, 5-year CAGR — 17.19% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ARTV SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 24.16 10.37 4.97
Net debt to EBITDA 1.24 3.23 1.01

Dividend

Metric ARTV SLGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARTV SLGL Biotechnology median
Market cap 202.89m 199.75m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack